Collectively, our study underscores the crucial oncogenic role of ZNF217 in B-ALL and unveils novel insights into the molecular mechanisms underlying the pathogenesis of high-risk B-ALL, paving the way for the development of more effective targeted therapies for high-risk B-ALL. Here, ZNF217 is linked to acute lymphoblastic leukemia.